Skip to main content

Table 4 Ability of CEA and CYFRA 21-1 to predict DCR (CR + PR + SD) in a multivariate analysis

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

 

Odds ratio

95% CI

p-value

Gender

Male

1.0

 

0.13

Female

1.85

(0.8–4.1)

Age

 ≤ 70

1.0

 

0.48

 > 70

1.31

(0.6–2.8)

CEA reduction ≥ 20%

No

1.0

 

0.32

Yes

1.58

(0.6–3.9)

CYFRA 21-1 reduction ≥ 20%

No

1.0

 

0.002

Yes

4.36

(1.7–11.3)

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us